川田 一郎

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Lung Neoplasms 80%
3. osimertinib 43%
4. Protein-Tyrosine Kinases 38%
5. Mutation 36%
6. ErbB Receptors 30%
7. Afatinib 22%
8. Therapeutics 21%
9. Neoplasms 20%
10. Adenocarcinoma of Lung 18%
11. S 1 (combination) 16%
12. Lung 16%
13. Anaplastic Lymphoma Kinase 14%
14. Receptor Protein-Tyrosine Kinases 14%
15. Nivolumab 14%
16. Malignant Mesothelioma 13%
17. Cell Line 13%
18. Cetuximab 13%
19. Irinotecan 12%
20. Exons 12%
21. N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 11%
22. Drug Therapy 11%
23. (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo(d)imidazol-2-yl)-2-methylisonicotinamide 11%
24. naquotinib 11%
25. Insertional Mutagenesis 10%
26. CH5424802 10%
27. Esophageal Neoplasms 10%
28. Elderly 10%
29. Pemetrexed 10%
30. Japan 10%
31. Crizotinib 10%
32. AEE 788 10%
33. ARQ 197 9%
34. benralizumab 9%
35. 1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 9%
36. favipiravir 9%
37. Annular Erythema 9%
38. Multicenter Studies 9%
39. rice bran saccharide 8%
40. Interstitial Lung Diseases 8%
41. Caregivers 8%
42. navitoclax 8%
43. Methylation 8%
44. Erlotinib Hydrochloride 8%
45. Pneumonia 8%
46. Survival 8%
47. Histone-Lysine N-Methyltransferase 8%
48. Adrenal Cortex Hormones 8%
49. Safety 7%
50. Epigenomics 7%